Stock Ratings / Health Care / AEON / earnings

MRKR (48) NEUP (32) AKTX (36) RADX (61) ⌘ Pro Terminal →

AEON Biopharma Inc. (Class A) (AEON) Next Earnings Date & Expected ±12.5% Move

$0.29 +11.36% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

AEON Biopharma Inc. (Class A) (AEON) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $17.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-3.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEON)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.04 Expected Swing

MODEL EARNINGS SETUP GAUGE

AEON Quantitative Pre-Earnings Setup: 48/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (48/100)Model Risk Weight (52/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$39.2M	-$17.3M	52%
FY 2024	2024-12-31	$0	$42.0M	-$20.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEON)

✓Walkthrough of AEON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AEON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.48%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.28H $0.29L $0.27C $0.29VOL 774.4K

RES: $0.46SUP: $0.23SMA50: $0.26SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AEON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AEON Butterfly Map → + Track AEON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AEON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AEON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AEON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEON)

Health Care Rank #393 of 1016 ⚔️ MRKR vs AEON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AEON vs. MRKR, NEUP, AKTX, RADX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AEON Biopharma Inc. (Class A) (AEON) ranks #393 by composite RQD confidence (48/100, grade D) and #844 by equity capitalization ($17.4M). Within this direct 5-issuer industry benchmark cohort, AEON leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AEON at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AEON ACTIVE AEON Biopharma Inc. (Class A)	D	48/100	—	—	-35.0%	+11.36%	$17.4M	Benchmark Subject
MRKR Marker Therapeutics Inc.	D	48/100	—	—	-35.0%	+1.00%	$16.8M	/mrkr-vs-aeon →
NEUP Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	/neup-vs-aeon →
AKTX Akari Therapeutics plc ADS	D-	36/100	—	—	-35.0%	-13.04%	$18.3M	/aktx-vs-aeon →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-aeon →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001837607

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AEON Biopharma Inc. (Class A) (AEON) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.2M, operating cash flow of -$17.3M, and free cash flow of -$17.3M (+14.7% YoY). On the balance sheet, AEON closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$39.2M	-$17.3M	-$17.3M	$5.6M	—
FY2024 (FY)	2024-12-31	$0	$42.0M	-$20.3M	-$20.3M	$3.1M	—

3. AEON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AEON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AEON Biopharma Inc. (Class A) (NYSE: AEON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $0.29 (+11.36% 1D, market cap $17.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEON ranks #393 in composite RQD confidence.

How does AEON compare to MRKR and NEUP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AEON carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M). Among the 5-stock peer group, AEON leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AEON?

Per AEON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837607), AEON Biopharma Inc. (Class A) generated $0 in revenue, -$39.2M in net income, and -$17.3M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AEON trading relative to its 50-day, 200-day, and 52-week technical levels?

AEON last traded at $0.29 (+11.36% on volume of 1,345,357 shares), positioning the stock +11.54% above its 50-day simple moving average ($0.26) and -57.35% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.18 to $1.45, AEON sits at the 8.7% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.33).